Garheng Kong M.D., Ph.D.
Dr. Garheng Kong has served as a director of the Company since December 1, 2013. Dr. Kong is the Managing Partner of HealthQuest Capital, a healthcare-focused investment firm, and was previously a general partner at Sofinnova Ventures, a position he held from 2010 to 2013. Before joining Sofinnova, Dr. Kong was a general partner from 2000 to 2010 at Intersouth Partners, a venture capital firm where he was a founding investor or board member for various life science ventures, several of which were acquired by large pharmaceutical companies. Prior to his investing career, Dr. Kong was employed by GlaxoSmithKline, McKinsey & Company, and TherOx. Dr. Kong has served on the Board of Directors of Avedro, Inc., a commercial-stage ophthalmic medical technology company, (NASDAQ: AVDR) since April 2017 which he joined in connection with an investment by HealthQuest Capital. Dr. Kong has served on the board of Alimera Sciences, Inc. a pharmaceutical company that specializes in the commercialization and development of ophthalmic pharmaceuticals (NASDAQ: ALIM) since October 2012, when Sofinnova Ventures made an investment in Alimera. Dr. Kong also serves on the Compensation Committee of Alimera Sciences and previously served as the Chairman of the Compensation Committee from June 2018 to June 2019. Dr. Kong has served on the board of directors of Strongbridge Biopharma plc (NASDAQ: SBBP) since 2015. Dr. Kong previously served on the Board of Melinta Therapeutics, a pharmaceutical company formerly known as Cempra Pharmaceuticals (NASDAQ: CEMP), from September 2006 until June 2019, and served as Chairman of the Board from 2008 to 2017 as well as Chairman of the Compensation Committee during that time. Dr. Kong has previously served on the board of directors of Histogenics Corporation (NASDAQ: HSGX) a public biotechnology company, from July 2012 until February 2019, which he joined in connection with an investment by Sofinnova Ventures. Dr. Kong also sits on the Duke University Medical Center Board of Visitors.